Alto Neuroscience (ANRO)
NYSE Market Closed
Alto Neuroscience Inc. is a clinical-stage biotechnology company developing psychiatric medicines with a precision-medicine approach. Rather than treating depression or schizophrenia as uniform conditions, Alto seeks to match drug candidates with patient groups defined by objective measures of brain biology. Its work is built around biomarkers that may include neurocognitive tests, electrophysiology, wearable data, and other brain-based signals intended to identify patients more likely to respond to a specific therapy.
The company’s pipeline is led by multiple clinical-stage programmes, including ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300. These candidates are being evaluated initially in major depressive disorder, other depressive conditions, and schizophrenia-related populations. Alto’s strategy reflects a broader shift in neuroscience drug development toward patient stratification, where clinical trials are designed around biologically defined subgroups instead of relying only on symptom-based diagnoses.
Alto is not a commercial-stage pharmaceutical company and its value depends heavily on clinical data, regulatory progress, intellectual property, and its ability to finance development. The company operates in an area with substantial unmet need, as many psychiatric patients do not respond adequately to existing medications and treatment selection often relies on trial and error. By combining drug development with biomarker-led trial design, Alto aims to improve response rates, shorten the path to effective treatment, and create differentiated therapies in markets that have historically been difficult for new medicines to penetrate.
Last updated
- Market Cap
- 661.52M
- P/E
- —
- P/FCF
- —
- P/S
- —
- Enterprise Value
- 416.11M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Address
- 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, CA, 94041
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Investors who lost money on Alto Neuroscience, Inc.(ANRO) should contact Levi & Korsinsky about pending Class Action - ANRO
ANRO DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
ANRO DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ANRO DEADLINE NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO
Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANRO
ANRO IMPORTANT DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ANRO DEADLINE: ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Alto Neuroscience, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight
ANRO DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Alto Neuroscience, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ANRO
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit – ANRO
ANRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Alto Neuroscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors of Class Actions Against Neogen, Alto, RxSight, and Replimune and Encourages Investors to Contact the Firm
ANRO DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ANRO
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 661.52M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 416.11M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.72
- P/S
P/S ratio compares a company's share price to its revenue per share.
- —
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -5.39
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- —
- EPS
- -2.12
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -62.86M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -30.53%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -26.9%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.08
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 20.52
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 20.52
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 20.11
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 303.78K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 18.85
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -27.14M | -17.06M | -14.95M | -18.68M | -15.68M |
| EBITDA | -26.95M | -16.9M | -14.79M | -18.51M | -15.51M |
| Net income | -26.24M | -16.18M | -14.18M | -17.71M | -15.17M |
| Basic EPS | -0.8 | -0.45 | -0.52 | -0.65 | -0.56 |
| Diluted EPS | -0.8 | -0.45 | -0.52 | -0.65 | -0.56 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 276.26M | 184.69M | 147.01M | 157.88M | 171.92M |
| Total liabilities | 32.89M | 33.55M | 35.45M | 34.47M | 32.82M |
| Total equity | 243.37M | 151.14M | 111.56M | 123.41M | 139.1M |
| Cash & equivalents | 263.76M | 176.48M | 137.82M | 147.59M | 160.75M |
| Current assets | 269.13M | 177.72M | 139.45M | 149.85M | 163.52M |
| Current liabilities | 13.12M | 11.33M | 9.05M | 8.13M | 7.26M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -27.09M | -11.52M | -9.92M | -13.78M | -16.56M |
| Investing cash flow | -556K | 0 | 0 | 0 | -24K |
| Financing cash flow | 114.94M | 50.19M | 153K | 613K | 9.13M |
| Change in cash | 87.28M | 38.67M | -9.77M | -13.17M | -7.48M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 3 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 8-K — Alto Neuroscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Miller Andrew Craig | View Filing | |
| edgar index | SCHEDULE 13G/A — Alto Neuroscience, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Alto Neuroscience, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Alto Neuroscience, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| form 4 | Form 4 — Etkin Amit | View Filing | |
| edgar index | 8-K — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 10-Q — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 8-K — Alto Neuroscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Dreyfus Andrew | View Filing | |
| form 4 | Form 4 — Sanchez Ramiro | View Filing | |
| form 4 | Form 4 — Cox Christopher Nixon | View Filing | |
| form 4 | Form 4 — York Gwill | View Filing | |
| form 4 | Form 4 — Manji Husseini | View Filing | |
| edgar index | EFFECT — Alto Neuroscience, Inc. | View Filing | |
| edgar index | CORRESP — Alto Neuroscience, Inc. | View Filing | |
| edgar index | UPLOAD — Alto Neuroscience, Inc. | View Filing | |
| edgar index | S-3 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 8-K — Alto Neuroscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | DEF 14A — Alto Neuroscience, Inc. | View Filing | |
| edgar index | DEFA14A — Alto Neuroscience, Inc. | View Filing | |
| edgar index | ARS — Alto Neuroscience, Inc. | View Filing | |
| edgar index | S-8 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 8-K — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 8-K — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 10-K — Alto Neuroscience, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| form 4 | Form 4 — Etkin Amit | View Filing | |
| form 4 | Form 4 — Smith Nicholas Conrad | View Filing | |
| edgar index | SCHEDULE 13G/A — Alto Neuroscience, Inc. | View Filing | |
| edgar index | SCHEDULE 13G — Alto Neuroscience, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Alto Neuroscience, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Alto Neuroscience, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Alto Neuroscience, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Alto Neuroscience, Inc. | View Filing | |
| edgar index | SCHEDULE 13G/A — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| form 4 | Form 4 — Hanley Jr. Michael Conick | View Filing | |
| form 4 | Form 4 — Etkin Amit | View Filing | |
| form 4 | Form 4 — Savitz Adam | View Filing | |
| form 4 | Form 4 — Smith Nicholas Conrad | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 4 — Alto Neuroscience, Inc. | View Filing | |
| form 4 | Form 4 — Sanchez Ramiro | View Filing | |
| form 4 | Form 4 — Cox Christopher Nixon | View Filing | |
| form 4 | Form 4 — York Gwill | View Filing | |
| form 4 | Form 4 — Manji Husseini | View Filing | |
| edgar index | EFFECT — Alto Neuroscience, Inc. | View Filing | |
| edgar index | CORRESP — Alto Neuroscience, Inc. | View Filing | |
| edgar index | S-3 — Alto Neuroscience, Inc. | View Filing | |
| edgar index | 8-K — Alto Neuroscience, Inc. | View Filing |